Refine
Has Fulltext
- yes (20)
Is part of the Bibliography
- yes (20)
Document Type
- Journal article (20)
Language
- English (20)
Keywords
- prostate cancer (8)
- radioligand therapy (6)
- PSMA (4)
- PET/CT (3)
- theranostics (3)
- CXCR4 (2)
- PSMA I&T (2)
- adrenocortical carcinoma (2)
- endoradiotherapy (2)
- radiotherapy (2)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- C-X-C motif chemokine receptor 4 (1)
- CNS cancer (1)
- COVID-19 (1)
- CTCAE (1)
- CXCR4-targeting (1)
- CYP11B enzymes (1)
- DOTA-EB-TATE (1)
- E-cadherin (1)
- FDG (1)
- IMAZA (1)
- NEC (1)
- NET (1)
- PET (1)
- PSA (1)
- PSA response (1)
- PSMA PET/CT (1)
- PSMA-617 (1)
- PSMA-RADS (1)
- PSMA-TV (1)
- PSMA‐617 (1)
- RLT (1)
- SARS-CoV-2 (1)
- SUV (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]Lu-PSMA I&T (1)
- [68Ga]PentixaFor (1)
- \(^{177}\)Lu (1)
- \(^{18}\)F-PSMA-1007 (1)
- adrenal incidentaloma (1)
- agreement (1)
- attention deficit/hyperactivity disorder (ADHD) (1)
- beta-catenin (1)
- biokinetics (1)
- biomarker (1)
- bone-marrow (1)
- caudate nucleus (1)
- comparability (1)
- dopamine transporter (DAT) (1)
- evans blue (1)
- flare phenomenon (1)
- hematotoxicity (1)
- intraindividual comparison (1)
- late response (1)
- macroscopic recurrence (1)
- matched pair (1)
- meningioma (1)
- metabolic tumour volume (MTV) (1)
- methylphenidate (1)
- molecular imaging (1)
- nephrotoxicity (1)
- outcomes research (1)
- overall survival (1)
- peptide receptor radionuclide therapy (PRRT) (1)
- prediction (1)
- prostate-specific membrane antigen (1)
- prostate-specific membrane antigen (PSMA) (1)
- responsivity (1)
- salvage radiotherapy (1)
- simultaneous integrated boost (1)
- single photon emission computed tomography (SPECT) (1)
- software (1)
- somatostatin receptor (1)
- staging (1)
- standardized reporting system (1)
- striatum (1)
- taxane (1)
- total lesion PSMA (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (20)
- Urologische Klinik und Poliklinik (9)
- Klinik und Poliklinik für Strahlentherapie (3)
- Medizinische Klinik und Poliklinik I (3)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Pathologisches Institut (2)
- Comprehensive Cancer Center Mainfranken (1)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
- Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (1)
Background
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is increasingly incorporated in the therapeutic algorithm of patients with metastatic castration-resistant prostate cancer (mCRPC). We aimed to elucidate the predictive performance of early biochemical response for overall survival (OS).
Materials and Methods
In this bicentric analysis, we included 184 mCRPC patients treated with \(^{177}\)Lu-PSMA RLT. Response to treatment was defined as decrease in prostate-specific antigen (PSA) levels 8 weeks after the first cycle of RLT (any decline or >50% according to Prostate Cancer Working Group 3). OS of responders and nonresponders was then compared using Kaplan–Meier curves and log-rank comparison.
Results
A total of 114/184 patients (62.0%) showed any PSA decline (PSA response >50%, 55/184 [29.9%]). For individuals exhibiting a PSA decline >50%, OS of 19 months was significantly longer relative to nonresponders (13 months; hazard ratio of death [HR] = 0.64, 95% confidence interval [95% CI] = 0.44–0.93; p = 0.02). However, the difference was even more pronounced for any PSA decline, with an OS of 19 months in responders, but only 8 months in nonresponders (HR = 0.39, 95% CI = 0.25–0.60; p < 0.001).
Conclusions
In mCRPC patients scheduled for RLT, early biochemical response was tightly linked to prolonged survival, irrespective of the magnitude of PSA decline. As such, even in patients with PSA decrease of less than 50%, RLT should be continued.